Table 2.
Transfection method* | Transfection efficiency† | Random integration‡ | Site-specific integration§ | Gene targeting¶ | Targeting ratio‖ |
---|---|---|---|---|---|
Microinjection | ND | 1.2 × 10−1 | ND | 8 × 10−3 | 1 :15 |
Electroporation | 10% (30) | 8.7 × 10−4 | 2.2 × 10−7 | 2.1 × 10−7 | 1 :2,400 |
Calcium phosphate | 24% (155) | 2.5 × 10−2 | 1.2 × 10−4 | 6.3 × 10−7 | 1 :40,000 |
Fugene-6 | 92% (22) | 4.8 × 10−2 | 7.2 × 10−4 | 1.3 × 10−7 | 1 :370,000 |
LipofectAmine | 98% (257) | 2.2 × 10−1 | 1.5 × 10−3 | 6.2 × 10−7 | 1 :350,000 |
ND, not determined.
Microinjection (G. N. Proctor, and J.H.W., unpublished work) used vector pAG-7 and cell line CHO-ATS-49tg (174). Mass delivery methods used vector pGS100, cell line RMP41 (175), and published protocols (175–178).
Transfection efficiency was measured by FACS analysis of cells transfected with plasmid pEYFP-N1 (177). Counting gates were set to include 99% of cells treated in the absence of DNA. Percentages indicate the fraction of treated cells shifted across the counting gate after transfection; numbers in parentheses indicate the mean fluorescence intensity (arbitrary units) of the shifted population.
Random integration was measured by selecting for GPT+ colonies after transfection of XhoI-linearized pGS100 (175).
FLP/FRT-mediated site-specific integration of pGS100 into the APRT gene in RMP41 cells was measured after cotransfection of circular pGS100 and pOG44, which expresses the FLP recombinase (175).
Targeted HR was measured by selecting for APRT+ colonies after transfection of XhoI-linearized pGS100 (175).
The targeting ratio is targeted recombinants to random integrants.